All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution
Authors: Grimm D
CellNetworks People: Grimm Dirk
Journal: Mol Ther. 2012 Sep;20(9):1661-3. doi: 10.1038/mt.2012.173

Roughly two decades after its discovery and cloning, hepatitis C virus (HCV)—a pathogen infecting up to 180 million people worldwide and capable of causing severe liver disease, including cirrhosis and hepatocellular carcinoma—remains a frustrating target for development of antiviral therapies. Two articles in this issue of Molecular Therapy now report combinatorial RNA interference (coRNAi) strategies against multiple HCV genotypes that aim to balance in vivo safety, efficiency, and specificity, and that promise to restrict viral escape mutants.